OptiNose (OPTN)
(Delayed Data from NSDQ)
$0.76 USD
-0.03 (-4.27%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.75 -0.01 (-1.52%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OPTN 0.76 -0.03(-4.27%)
Will OPTN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OPTN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPTN
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
OPTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Other News for OPTN
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose announces peer-review publication on EDS-FLU efficacy
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
Optinose’s XHANCE Poised for Market Expansion and Growth: A Buy Rating Review